Renovacor, Inc., (RCOR): Price and Financial Metrics
GET POWR RATINGS... FREE!
RCOR Stock Price Chart Interactive Chart >
RCOR Price/Volume Stats
|Current price||$3.20||52-week high||$9.74|
|Prev. close||$3.05||52-week low||$1.34|
|Day high||$3.20||Avg. volume||30,033|
|50-day MA||$2.74||Dividend yield||N/A|
|200-day MA||$3.00||Market Cap||55.26M|
Renovacor, Inc., (RCOR) Company Bio
Renovacor, Inc., an early-stage biotechnology company, engages in developing a pipeline of adeno-associated virus (AAV) based gene therapies for Bcl2-associated athanogene 3 (BAG3) associated diseases. Its lead program is recombinant AAV-based gene therapy for patients suffering from dilated cardiomyopathy (DCM) due to mutations in the BAG3 gene; and REN-001, an AAV9-based gene therapy to treat BAG3-associated DCM. The company was incorporated in 2013 and is based in Greenwich, Connecticut.
Most Popular Stories View All
RCOR Latest News Stream
|Loading, please wait...|
RCOR Latest Social Stream
View Full RCOR Social Stream
Latest RCOR News From Around the Web
Below are the latest news stories about RENOVACOR INC that investors may wish to consider to help them evaluate RCOR as an investment opportunity.
Renovacor Announces Upcoming Presentation at the 29th European Society of Gene & Cell Therapy Congress
CAMBRIDGE, Mass., October 10, 2022--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced that the results of analytical and biophysical assays conducted as part of the company’s chemistry, manufacturing, and controls (CMC) development process for REN-001 will be featured in an upcoming poster presentat
Renovacor Announces Upcoming Presentation at Keystone Symposia’s Heart Failure: Mechanisms and Therapies Conference
CAMBRIDGE, Mass., September 26, 2022--Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today announced that preclinical studies characterizing the progression of cardiac dysfunction and mortality in a BAG3 haploinsufficiency mouse model of dilated cardiomyopathy will be featured in an upcoming poster presentation
Shares of Renovacor (NYSE: RCOR) were up in early morning trading on Tuesday following the news of its acquisition by Rocket Pharmaceuticals (RCKT). Rocket will acquire Renovacor in an all-stock deal for $2.60 per share, based on the volume-weighted average trading price of Rocket stock priced at $15.51 for the 30 trading days through and including Monday, September 19. Renovacor is a biotechnology company focused on delivering innovative precision therapies for genetic cardiovascular diseases. As a part of this deal, Renovacor shareholders will receive around 0.1676 shares of Rocket in exchange for each of their shares in Renovacor and upon the close of the transaction, will own approximately 4.
The Federal Reserve is planning to reveal additional interest rate hikes tomorrow that investors will want to know about!
Rumble (RUM) stock is on the move Tuesday as the YouTube alternative is seeing volatility during its second day of trading.
RCOR Price Returns